<DOC>
	<DOCNO>NCT02628392</DOCNO>
	<brief_summary>The objective study evaluate efficacy , safety , dose DS-8500a compare placebo patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Phase 2 Study DS-8500a Japanese Subjects With Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description>The objective study evaluate efficacy , safety , dose DS-8500a compare placebo patient type 2 diabetes mellitus 12-week oral administration DS-8500a 25 , 50 , 75 mg double-blind , parallel-group comparison study . In addition , clinical position DS-8500a relative exist drug investigate use sitagliptin comparator .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients age ≥ 20 year time inform consent Japanese patient type 2 diabetes Patients HbA1c ≥ 7.0 % &lt; 10.0 % Patients type 1 diabetes mellitus history diabetic coma , precoma , ketoacidosis Patients receive require treatment insulin Patients body mass index ( BMI ) &lt; 18.5 kg/m2 ≥ 35.0 kg/m2 Patients clinically evident renal impairment ( estimate glomerular filtration rate [ eGFR ] &lt; 45 mL/min per 1.73 m2 ) clinically significant renal disease Patients fast plasma glucose ≥ 240 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Adult</keyword>
	<keyword>Developmental Phase II</keyword>
</DOC>